Posted by Michael Wonder on 23 Nov 2016
Halaven cleared by TGA for sarcoma
23 November 2016 - Eisai bags a second use for its halichondrin B analogue.
The TGA approved Halaven on 18 November 2016 for the treatment of patients with unresectable liposarcoma who have received prior chemotherapy for advanced or metastatic disease.
